Mainz Biomed B.V.
MYNZ · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | -23.2% | -28.3% | 142.5% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -108.2% | 68.6% | 61.3% | 18.7% |
| R&D Expenses | $3 | $3 | $3 | $4 |
| G&A Expenses | $3 | $4 | $5 | $4 |
| SG&A Expenses | $5 | $6 | $7 | $9 |
| Sales & Mktg Exp. | $2 | $2 | $2 | $1 |
| Other Operating Expenses | $0 | $1 | $0 | $1 |
| Operating Expenses | $8 | $9 | $10 | $14 |
| Operating Income | -$8 | -$9 | -$10 | -$12 |
| % Margin | -2,822.1% | -2,381.5% | -1,883.2% | -5,695.2% |
| Other Income/Exp. Net | -$0 | -$2 | -$1 | $1 |
| Pre-Tax Income | -$8 | -$11 | -$11 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$11 | -$11 | -$5 |
| % Margin | -2,910.3% | -2,847.4% | -2,116.8% | -2,413.5% |
| EPS | -2.65 | -7.71 | -19.73 | -11.73 |
| % Growth | 65.6% | 60.9% | -68.2% | – |
| EPS Diluted | -2.65 | -7.71 | -19.73 | -11.73 |
| Weighted Avg Shares Out | 3 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 3 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$8 | -$10 | -$9 | -$13 |
| % Margin | -2,700.7% | -2,702.8% | -1,818.7% | -5,872% |